NR3C2 and neoplasm: CCR1 inhibition, on the other hand, suppresses the accumulation of MR+Ly6C- pro-tumour IM at later stages, accompanied by the expansion of the AM compartment and infiltration of NK cells, resulting in reduced metastatic burden (Fig. 7).